1. Home
  2. OIS vs TRDA Comparison

OIS vs TRDA Comparison

Compare OIS & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oil States International Inc.

OIS

Oil States International Inc.

HOLD

Current Price

$11.16

Market Cap

682.7M

Sector

Industrials

ML Signal

HOLD

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$14.19

Market Cap

481.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OIS
TRDA
Founded
1995
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
682.7M
481.6M
IPO Year
2000
2021

Fundamental Metrics

Financial Performance
Metric
OIS
TRDA
Price
$11.16
$14.19
Analyst Decision
Buy
Strong Buy
Analyst Count
2
3
Target Price
$14.00
$21.00
AVG Volume (30 Days)
782.9K
162.5K
Earning Date
04-30-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,088,133,000.00
$25,421,000.00
Revenue This Year
$3.73
$39.97
Revenue Next Year
$5.36
$50.80
P/E Ratio
N/A
N/A
Revenue Growth
62.26
N/A
52 Week Low
$3.33
$4.93
52 Week High
$14.50
$14.36

Technical Indicators

Market Signals
Indicator
OIS
TRDA
Relative Strength Index (RSI) 43.89 61.47
Support Level $5.72 $10.84
Resistance Level $12.79 N/A
Average True Range (ATR) 0.49 0.75
MACD -0.09 0.12
Stochastic Oscillator 21.04 87.79

Price Performance

Historical Comparison
OIS
TRDA

About OIS Oil States International Inc.

Oil States International Inc is a provider of manufactured products and services to customers in the energy, military and industrial sectors. The company operates through three business segments - Offshore Manufactured Products, Completion and Production Services and Downhole Technologies. Its customers include many national oil and natural gas companies, and independent oil and natural gas companies, offshore drilling companies and other oilfield service, defense and industrial companies.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: